The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Oklahoma City Indian Clinic announced it has received a $250,000 charitable contribution from Pfizer to support programs ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

Charlotte Allerton, Pfizer's head of medicine design, said: "The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities. "We are looking forward to potentially ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Pfizer targets $4 billion in operational savings ... molecular profiles (a trend increasingly favored in precision medicine). In short, the pipeline diversity here enables near-term commercial ...